Merck & Co. Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection

Press/Media: Press / Media

PeriodNov 14 2016

Media coverage

1

Media coverage

  • TitleMerck & Co. Announces Findings For Investigational Triple-Combination Chronic Hepatitis C Therapy Showing High Rates Of Sustained Virologic Response In People With Genotypes 1, 2 Or 3 Infection
    Media name/outletBioSpace
    CountryUnited States
    Date11/14/16
    PersonsEric J Lawitz